Search EN menu en EIB GROUP CLIENT PORTAL
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

Signature(s)

Amount
€ 100,000,000
Countries
Sector(s)
Denmark : € 100,000,000
Industry : € 100,000,000
Signature date(s)
11/08/2017 : € 100,000,000
Link to source

Summary sheet

Release date
7 April 2017
Status
Reference
Signed | 17/08/2017
20160208
Project name
Promoter - financial intermediary
NOVOZYMES BIOTECHNOLOGY INNOVATION
NOVOZYMES A/S
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 100 million
EUR 232 million
Location
Sector(s)
Description
Objectives

Financing of Novozymes' research, development and innovation (RDI) activities for the development of biological solutions, industrial enzymes and microorganisms

The project concerns the financing of RDI activities in Denmark for the period 2017-2018, for the development of biological solutions, industrial enzymes and microorganisms. The RDI activities included in the project will be implemented in alignment with the existing RDI streams.

Environmental aspects
Procurement

The project mainly concerns investments in research and development (R&D) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

The promoter has been assessed by the EIB as being a private company not operating in the utilities sector and not having the status of a contracting entity, thus not subject to EU rules on public procurement. However, if after the project appraisal, the EIB were to conclude that the promoter is after all subject to EU public procurement legislation (i.e. Directive 2014/25/EU), then the Bank would require the promoter to ensure that contracts for the implementation of the project have been/will be tendered in accordance with the relevant applicable EU procurement legislation (Directive 2014/25/EU and Directive 92/13/EEC) as interpreted by the Court of Justice of the EU, with publication of tender notices in the Official Journal of the EU, as and where required.

Link to source
Other links

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

Documents

Environmental and Social Data Sheet (ESDS) - NOVOZYMES BIOTECHNOLOGY INNOVATION
Publication Date
22 Aug 2017
Document language
Main Topic
Lending
Document Number
74393776
Document Focus
Environmental Information
Project Number
20160208
Sector(s)
Regions
Countries
Publicly available
Download now
Environmental and Social Completion Sheet (ESCS) - NOVOZYMES BIOTECHNOLOGY INNOVATION
Publication Date
10 Jan 2020
Document language
Main Topic
Lending
Document Number
125099961
Document Focus
Environmental Information
Project Number
20160208
Sector(s)
Regions
Countries
Publicly available
Download now

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications